Tamiflu - Oseltamivir Production

Oseltamivir is an antiviral drug used in the treatment and prophylaxis of both influenza virus A and influenza virus B. It was approved for seasonal influenza by the US Food and Drug Administration (FDA) in 1999, and approval from Japanese agencies and the European Medicines Agency (EMA) followed soon afterward.

The pharmaceutical company Roche launched oseltamivir in the global market with Tamiflu as its brand name. In 2007 alone this pharmaceutical company was producing 400 million doses of the drug with a market value of 2.2 billion US dollars, and has benefitted by more than 18 billion US dollars since the launch of the drug.

Image Credit: M.Moira / Shutterstock
Image Credit: M.Moira / Shutterstock

Synthesis from shikimic acid

In the pharmaceutical industry, shikimic acid (3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid) is used as a base material for the production of oseltamivir. The availability of this acid is the major bottleneck in oseltamivir production, as it cannot be synthesized economically and is only effectively isolated from Chinese star anise (Illicium verum), an ancient cooking spice.

A low isolation yield of shikimic acid from Illicium verum is blamed for the 2005 shortage of oseltamivir. Chinese star anise is susceptible to vagaries of weather, which is the reason why supply from this plant has experienced difficulties. In addition, extraction and purification from seeds are expensive, with the tree taking approximately six years from planting to bear fruit.

In this context, the fermentation route to produce shikimic acid from renewable resources has become increasingly attractive. Shikimic acid produced through fermentation is most successfully produced by rationally designed strains of Escherichia coli by blocking the aromatic amino acid pathway after the production of shikimic acid.

An alternate way is to make shikimic acid as a result of dephosphorylation of shikimate-3-phosphate. Engineering the uptake of carbon, central metabolism, the regulatory circuits and the common aromatic pathway (including shikimic acid import) have all been proposed to affect higher productivities and lower by-product creation.

Biotransformation of quinic acid can also be pursued as an alternative microbial route. Certain microorganisms (such as Aspergillus, Achromobacter and Pseudomonas) can use quinic acid as the sole carbon source to produce aromatic amino acids via the shikimic acid pathway. Strains of Escherichia coli specifically engineered for overproducing quinic acid from glucose have also been developed.

Newer routes for the production of oseltamivir without the use of shikimic or quinic acids have appeared, but have not been fully commercialized yet. For example, a novel synthesis route has been recently published that obviates raw materials and uses monotrimethylsilyl-acetylene (TMSA) on the easily accessible component 1,4-cyclohexadiene.

Formulations of oseltamivir

Oseltamivir is available in capsules with three dosage options (30, 45, and 75 mg), powder for oral suspension, and in intravenous form (predominately for clinical trials). Both 75 mg capsules and powder formulation have been shown to be bioequivalent dosage forms and can be stockpiled for use in a pandemic situation.

The capsules can be used for both treatment and prophylaxis in adolescent and adult patients. The powder formulation is primarily intended to enable children to receive the drug, but may also be used by adults who are unable to swallow capsules. Oseltamivir capsules have a shelf life of 5 years, powder formulation 24 months, and reconstituted solution 10 days (if stored at 2 to 8 °C).

Oseltamivir is available to governments in the magistral formulation. The active pharmaceutical ingredient is a water-soluble dry powder, with a very long shelf-life when stored in sealed drums. When dissolved in water (15 mg/mL) the solution is stable for three weeks if stored not above 25 °C, and for 6 weeks at 5 °C.

Nevertheless, it must be noted that this strategy depends upon sufficient pharmacy infrastructure to cope with large-scale reconstitution in the event of a pandemic. Furthermore, oseltamivir has a bitter taste, thus there is also a need for masking flavor (especially when giving the drug to young children).

Last Updated: Apr 8, 2021

Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2021, April 08). Tamiflu - Oseltamivir Production. News-Medical. Retrieved on January 31, 2023 from https://www.news-medical.net/health/Tamiflu-Oseltamivir-Production.aspx.

  • MLA

    Meštrović, Tomislav. "Tamiflu - Oseltamivir Production". News-Medical. 31 January 2023. <https://www.news-medical.net/health/Tamiflu-Oseltamivir-Production.aspx>.

  • Chicago

    Meštrović, Tomislav. "Tamiflu - Oseltamivir Production". News-Medical. https://www.news-medical.net/health/Tamiflu-Oseltamivir-Production.aspx. (accessed January 31, 2023).

  • Harvard

    Meštrović, Tomislav. 2021. Tamiflu - Oseltamivir Production. News-Medical, viewed 31 January 2023, https://www.news-medical.net/health/Tamiflu-Oseltamivir-Production.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment